Seattle, WA, United States of America

Susan Cottrell

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2005-2018

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Susan Cottrell

Introduction

Susan Cottrell is a prominent inventor based in Seattle, WA (US). She has made significant contributions to the field of biotechnology, particularly in the analysis of cell proliferative disorders. With a total of 4 patents to her name, her work has advanced the understanding of various medical conditions.

Latest Patents

Cottrell's latest patents include groundbreaking methods and nucleic acids for the analysis of colon cell proliferative disorders. These innovations provide methods for detecting, differentiating, or distinguishing between colon cell proliferative disorders by analyzing specific genes such as Versican, TPEF, H-Cadherin, Calcitonin, and EYA4. Additionally, she has developed methods and nucleic acids for analyzing gene expression associated with the development of prostate cell proliferative disorders. This application focuses on the detection and differentiation of prostate cell proliferative disorders through the analysis of gene expression status.

Career Highlights

Susan Cottrell is currently associated with Epigenomics AG, where she continues to push the boundaries of research in her field. Her work has not only contributed to scientific knowledge but has also paved the way for potential clinical applications.

Collaborations

Cottrell collaborates with esteemed colleagues such as Peter Adorjan and Matthias Burger, enhancing the impact of her research through teamwork and shared expertise.

Conclusion

Susan Cottrell's innovative work in the field of biotechnology exemplifies the importance of research in understanding and addressing medical challenges. Her contributions continue to influence the landscape of cell proliferative disorder analysis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…